| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-06-09 |
Ascensia Diabetes Care (Switzerland) Voluntis (France) |
insulin management solutions. |
type 2 diabetes |
development |
Metabolic diseases |
Development agreement |
| 2017-06-08 |
Vertex Pharmaceuticals (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-06-08 |
Boehringer Ingelheim (Germany) |
digital lab “BI X” |
|
establishment of a new subsidiary in the EU |
Technology - Services |
Establishment of a new subsidiary in the EU |
| 2017-06-08 |
Eli Lilly (USA - IN) KeyBioscience (Switzerland) |
Dual Amylin Calcitonin Receptor Agonists (DACRAs) including KBP-042, KBP-089 and KBP-056. |
metabolic diseases such as type 2 diabetes |
development |
Metabolic diseases |
Development agreement |
| 2017-06-08 |
Bluebird bio (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-06-07 |
AstraZeneca (UK) Grunenthal (Germany) |
Zomig® |
migraines, cluster headaches |
product acquisition |
CNS diseases - Neurological diseases |
Product acquisition |
| 2017-06-07 |
Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) |
commercial manufacturing facility in Clearwater |
|
opening of new premises |
Allergic diseases |
Opening of new premises |
| 2017-06-07 |
RegenXBio (USA - MD) Avexis (USA - IL) |
gene therapy treatments using RegenXbio’s NAV AAV9 vector |
Rett syndrome, genetic form of amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 (SOD1) gene |
|
Rare diseases - Genetic diseases - Neurological diseases |
Licensing agreement |
| 2017-06-06 |
Axovant Sciences (USA - NY) |
|
|
nomination |
CNS diseases - Neurological diseases |
Nomination |
| 2017-06-06 |
Crispr Therapeutics (Switzerland - UK) MaSTherCell (Belgium) |
CTX101 , allogeneic CAR-T therapies |
CD19 positive malignancies |
development - manufacturing - bioproduction |
Cancer - Oncology |
Development agreement |
| 2017-06-05 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-06-05 |
Novartis (Switzerland) IBM Watson Health (USA - NY) |
cognitive solution to provide insights on the expected outcomes of breast cancer treatment options |
breast cancer |
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2017-06-05 |
Myonexus Therapeutics (USA - OH) |
|
|
establishment of a new company in the US |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Establishment of a new subsidiary in the US |
| 2017-06-02 |
BMS (USA - NY) Seattle Genetics (USA - WA) |
Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) |
relapsed or refractory Hodgkin lymphoma, relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL) |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-06-02 |
Innate Pharma (France) Novo Nordisk (Denmark) |
anti-C5aR (IPH5401) |
|
product acquisition |
Cancer - Oncology |
Product acquisition |
| 2017-06-01 |
Inovio Pharmaceuticals (USA - PA) Roche (Switzerland) |
INO-5401, INO-9012 and atezolizumab |
advanced bladder cancer, specifically advanced unresectable or metastatic urothelial carcinoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-06-01 |
Takeda Pharmaceutical (Japan) |
new production facility at Grange Castle site |
|
construction of a production plant |
|
Construction of a production plant |
| 2017-06-01 |
Alexion Pharmaceuticals (USA - CT) |
head of research & development, chief human resources officer, chief compliance officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2017-05-31 |
AstraZeneca (UK) |
|
|
nomination |
|
Nomination |
| 2017-05-31 |
Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) |
binimetinib and encorafenib |
|
licensing, development, commercialisation |
|
Licensing agreement |
